The United States is on track to lose its official measles elimination status after a Pan American Health Organization review this week, and the bill for that failure is already arriving. More than 5,100 measles cases have been reported nationwide in 2026 as of early November, the country's worst outbreak in more than three decades, and eight deaths have been confirmed by states so far this year: six in Pennsylvania, one in New York and one in Wisconsin.

A new tool from researchers at Johns Hopkins University estimates that this year's outbreaks could cost nearly $83 million, including $56 million in public health response, almost $25 million in lost productivity and more than $1.8 million in direct medical expenses. The researchers are clear that these figures are estimates, not a definitive accounting. Even so, they show that the expense of a preventable disease does not stop at the hospital door. Health departments must trace contacts, notify exposed people and organize vaccination campaigns, and that work pulls staff away from other priorities.

The indirect costs are what should worry employers as much as public officials. Health economist Joey Mattingly estimated that each person quarantined after an exposure could cost roughly $300 in lost productivity. If one case exposes 40 to 50 people, that adds up to an estimated $12,000 to $15,000 in lost work, even if none of those contacts ever becomes sick. Parents miss shifts to care for children, and workers who do fall ill lose wages during recovery. Businesses are paying for the decisions behind falling childhood immunization rates whether or not they ever set a vaccination policy.

Bryan Patenaude, the Johns Hopkins health economist who helped build the tool, put the human side plainly: people who were never vaccinated as children, or who benefited from herd immunity, are now reaching adulthood and facing serious illness or death. That is a painful argument for acting now rather than after the next outbreak.

The response should be straightforward. States should fund contact tracing and vaccination outreach before outbreaks spread, and employers should make it easy for workers to get immunized and to take leave for exposure without penalty. The cost comparison is not close: the price of prevention is far lower than the millions in response and lost work that the data now documents. Measles is preventable, and the economic case for acting on that fact has never been clearer.